Literature DB >> 6219866

Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis.

M G Mutchnick, J A Schaffner, J A Prieto, F E Weller, A L Goldstein.   

Abstract

Mitogen-induced suppressor T lymphocyte function was evaluated in patients with chronic active hepatitis (CAH). The in vitro effect of the biological response modifier, thymosin fraction 5, on the suppressive activity of peripheral blood mononuclear cells (PBM) was also assessed. Suppressor cell activity was significantly decreased in patients with CAH when compared to controls (P less than 0.001). In the absence of the inducing mitogen, thymosin-treated PBM from both patients and controls promoted enhancement of tritiated thymidine uptake by cocultured allogeneic lymphocytes. When thymosin-treated mononuclear cells were mitogen-activated; patients, but not the controls, showed a marked increase in suppressor activity (P less than 0.001). These results indicate that the polypeptides contained in thymosin fraction 5 can promote a helper effect in patients and controls. Furthermore, PBM from patients with CAH contain a subset of lymphocytes that can express a suppressive function following thymosin treatment. We conclude that thymosin fraction 5 can promote an in vitro restoration of suppressor T cell function in patients with CAH.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6219866     DOI: 10.1007/bf01324949

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  46 in total

1.  Suppression by thymosin of pokeweed mitogen-induced differentiation of human B cells.

Authors:  R E Wolf; A L Goldstein; M Ziff
Journal:  Clin Immunol Immunopathol       Date:  1978-11

2.  Alteration in suppressor cell activity in chronic active hepatitis.

Authors:  H J Hodgson; J R Wands; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

3.  T-lymphocyte maturation: cell surface markers and immune function induced by T-lymphocyte cell-free products and thymosin polypeptides.

Authors:  A Ahmed; D M Wong; G B Thurman; T L Low; A L Goldstein; S J Sharkis; I Goldschneider
Journal:  Ann N Y Acad Sci       Date:  1979       Impact factor: 5.691

Review 4.  The suppressor-cell network in cancer (second of two parts).

Authors:  S Broder; T A Waldmann
Journal:  N Engl J Med       Date:  1978-12-14       Impact factor: 91.245

5.  Suppression of natural killer cell cytotoxicity by splenocytes from Corynebacterium parvum-injected, bone marrow-tolerant, and infant mice.

Authors:  C A Savary; E Lotzová
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

6.  Thymosin modulation of regulatory T cell function.

Authors:  M G Mutchnick; J A Prieto; J A Schaffner; F E Weller
Journal:  Clin Immunol Immunopathol       Date:  1982-06

7.  Radiosensitive, thymic hormone-sensitive peripheral blood suppressor cell activity in cancer patients.

Authors:  E M Hersh; Y Z Patt; S G Murphy; K Dicke; A Zander; M Adegbite; R Goldman
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

8.  Immunotherapy of patients with chronic virus B hepatitis. I. Maturation of human T-lymphocytes under influence of calf thymic hormone.

Authors:  M P Dabrowski; B K Dabrowska-Bernstein; W J Brzosko; L Babiuch; B Kassur
Journal:  Clin Immunol Immunopathol       Date:  1980-07

9.  Thymosin-induced reduction of "null cells" in peripheral-blood lymphocytes of patients with systemic lupus erythematosus.

Authors:  M A Scheinberg; E S Cathcart; A L Goldstein
Journal:  Lancet       Date:  1975-02-22       Impact factor: 79.321

10.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Thymic hormones--a clinical update.

Authors:  M B Sztein; A L Goldstein
Journal:  Springer Semin Immunopathol       Date:  1986
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.